{
    "clinical_study": {
        "@rank": "3004", 
        "arm_group": [
            {
                "arm_group_label": "dexmedetomidine", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "placebo group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "normal saline"
            }
        ], 
        "brief_summary": {
            "textblock": "Although the aetiology of emergence agitation (EA) derives from multiple factors, it is a\n      frequent side effect of sevoflurane anaesthesia in children. Dexmedetomidine, a potent\n      selective \u03b12-adrenergic agonist, can reduce the doses of hypnotics, opioids, analgesics, and\n      anaesthetics that must be concomitantly administered. This study was conducted to assess the\n      effect of dexmedetomidine infusion on sevoflurane requirements and recovery profiles with EA\n      in children undergoing ambulatory surgery."
        }, 
        "brief_title": "Effect of Dexmedetomidine on Sevoflurane Requirements and Emergence Agitation in Children Undergoing Ambulatory Surgery", 
        "completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "condition": "Ambulation Difficulty", 
        "condition_browse": {
            "mesh_term": "Mobility Limitation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  ASA class I\n\n          -  obtaining written informed consent from the parents\n\n          -  aged 1-5 years, and weighing <20 kg who were undergoing ambulatory hernioplasty or\n             orchiopexy\n\n        Exclusion Criteria:\n\n          -  mental retardation\n\n          -  developmental delays\n\n          -  neurological or psychiatric illnesses\n\n          -  coagulation disorder\n\n          -  spinal anomalies\n\n          -  bilateral procedures"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "5 Years", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01691001", 
            "org_study_id": "4-2011-0430"
        }, 
        "intervention": [
            {
                "arm_group_label": "dexmedetomidine", 
                "description": "dexmedetomidine(vs saline) 1 mcg/kg iv bolus during 10minutes, and  then, 0.1 mcg/kg/h dexmedetomidine(vs saline) was infused.", 
                "intervention_name": "Dexmedetomidine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo group", 
                "intervention_name": "normal saline", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Dexmedetomidine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 18, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "120-752"
                }, 
                "name": "Severance Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "the reduction rate of ET-sevo in achieving BIS scores from 45-50", 
            "safety_issue": "No", 
            "time_frame": "2 hour(during whole operation period)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01691001"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Yonsei University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yonsei University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}